GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Minerva Surgical Inc (OTCPK:UTRS) » Definitions » ROE %

Minerva Surgical (Minerva Surgical) ROE % : -122.64% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Minerva Surgical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Minerva Surgical's annualized net income for the quarter that ended in Sep. 2023 was $-28.72 Mil. Minerva Surgical's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $23.42 Mil. Therefore, Minerva Surgical's annualized ROE % for the quarter that ended in Sep. 2023 was -122.64%.

The historical rank and industry rank for Minerva Surgical's ROE % or its related term are showing as below:

UTRS' s ROE % Range Over the Past 10 Years
Min: -139.8   Med: -111.32   Max: -111.32
Current: -139.8

During the past 4 years, Minerva Surgical's highest ROE % was -111.32%. The lowest was -139.80%. And the median was -111.32%.

UTRS's ROE % is ranked worse than
91.06% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs UTRS: -139.80

Minerva Surgical ROE % Historical Data

The historical data trend for Minerva Surgical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Surgical ROE % Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROE %
- - - -111.32

Minerva Surgical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -173.00 -129.03 -177.05 -114.49 -122.64

Competitive Comparison of Minerva Surgical's ROE %

For the Medical Devices subindustry, Minerva Surgical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Surgical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minerva Surgical's ROE % distribution charts can be found below:

* The bar in red indicates where Minerva Surgical's ROE % falls into.



Minerva Surgical ROE % Calculation

Minerva Surgical's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-34.112/( (44.104+17.181)/ 2 )
=-34.112/30.6425
=-111.32 %

Minerva Surgical's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-28.724/( (26.587+20.255)/ 2 )
=-28.724/23.421
=-122.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


Minerva Surgical  (OTCPK:UTRS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-28.724/23.421
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-28.724 / 47.86)*(47.86 / 76.044)*(76.044 / 23.421)
=Net Margin %*Asset Turnover*Equity Multiplier
=-60.02 %*0.6294*3.2468
=ROA %*Equity Multiplier
=-37.78 %*3.2468
=-122.64 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-28.724/23.421
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-28.724 / -28.712) * (-28.712 / -24.384) * (-24.384 / 47.86) * (47.86 / 76.044) * (76.044 / 23.421)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0004 * 1.1775 * -50.95 % * 0.6294 * 3.2468
=-122.64 %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Minerva Surgical ROE % Related Terms

Thank you for viewing the detailed overview of Minerva Surgical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Surgical (Minerva Surgical) Business Description

Traded in Other Exchanges
N/A
Address
4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.
Executives
Daniel Cohen director C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Uri Geiger director, 10 percent owner 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Todd Usen director, officer: Chief Executive Officer C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054
Derrick Sung director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
David M Clapper director, officer: President and CEO 3003 TASMAN DRIVE, SANTA CLARA CA 95054
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jaffe Ross A Md director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Evgueni V. Skalnyi officer: VP Medical Affairs C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Dominique J. Filloux officer: COO C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Joel R Jung officer: CFO 1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Niquette L. Hunt director SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081
Jill Anderson director 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202

Minerva Surgical (Minerva Surgical) Headlines